Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Wells A. Messersmith et al.|Annals of Oncology|2021Cited by 371
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Haniel A. Araújo et al.|Cancer Discovery|2023Cited by 181
<p>Targeting Trop-2 in solid tumors: future prospects</p>Saif Zaman, Jhanelle E. Gray|OncoTargets and Therapy|2019Cited by 158
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Clinical Cancer Research|2024Cited by 42
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey Liveringhouse, Bradford A. Perez, Alberto Chiappori et al.|International Journal of Radiation Oncology*Biology*Physics|2023Cited by 18